Risk of pulmonary toxicity of bleomycin and filgrastim.
Magali Laprise-LachancePierre LemieuxJean-Pierre GrégoirePublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2018)
The results add further evidence that the concomitant use of filgrastim might not increase the risk of pulmonary toxicity of bleomycin. It also suggests that female patients might be more likely to develop this adverse effect. A clinical trial would be needed to confirm this result.